TCRX
TScan Therapeutics, Inc. · Healthcare · Market cap $29.1M
Insider Buying
$146K
reported purchases (SEC code P)
Insider Selling
$0
reported sales (SEC code S)
Unique Insiders
1
in the rolling window
Latest filing
Oct 2, 2026
Lynx1 Capital Management LP
TScan Therapeutics, Inc. (TCRX) has 3 SEC Form 4 filings (5 transaction rows) in the rolling window, disclosed by 1 distinct insider. Most recent filing: Oct 2, 2026.
Inside the rolling window, 1 insider at TScan Therapeutics, Inc. reported 3 open-market purchases totaling $146K and no open-market sales. The most active filer is 10% Owner Lynx1 Capital Management LP with 3 filings. The most recent open-market filing is a purchase of 80,069 shares by 10% Owner Lynx1 Capital Management LP, dated Dec 19, 2025, worth $72K.
- Industry:Biotechnology
- CEO:Gavin MacBeath
- Employees:139
- HQ:Waltham, MA, US
- IPO:2021-07-16
Earnings: last 7 quarters
Frequently asked questions
How many SEC Form 4 insider filings does TCRX have?
TScan Therapeutics, Inc. (TCRX) has 3 SEC Form 4 filings (5 transaction rows) in the rolling 365-day window, disclosed by 1 distinct insider. Most recent filing: Oct 2, 2026.
When was the most recent SEC Form 4 filing for TCRX?
The most recent Form 4 filing for TCRX on Tracefour is dated Oct 2, 2026.
Who is the most active insider at TCRX?
The most active SEC Form 4 filer at TCRX in the rolling window is 10% Owner Lynx1 Capital Management LP, with 3 filings.
What is the total insider buy and sell value at TCRX in the current window?
Inside the rolling window, insiders at TCRX bought $146K and sold $0 based on SEC Form 4 filings.
Can I get alerts for TCRX insider trading?
Yes. Tracefour sends a free email when a new SEC Form 4 purchase or sale is filed at TScan Therapeutics, Inc. (TCRX). Alerts are set per company from the page itself, there is no paid tier, and each email links to the original filing on SEC EDGAR.
Related companies
TScan Therapeutics, Inc. is in the Healthcare sector.